A New Standard of Automated Cell counter
ADAM™-MC, the automated fluorescence cell counter, performs viability and cell counting measurements using the PI(Propidium Iodide) staining method of dead-cell staining combined with advanced image analysis.
- Less than 1 min to get results
- Automated image analysis
- Accurate result
- Sensitive CCD detection and precise automatic stage
- Auto focusing
ADVANTAGE #1
New Standard of Automated Cell Counting
The ADAM™ series automatic cell counter measures total cell numbers and cell viability through cutting-edge detection technologies.
Instead of trypan blue staining which can lead to inaccurate data, ADAM™ utilizes sensitive fluorescence dye staining, LED optics and CCD detection technologies.
ADVANTAGE #2
Principle of Viability Measurement (PI-Staining Method)
After the samples are stained with fluorescent dye, propidium iodide, which intercalates DNA to stain the nucleus of target cells, ADAM™-MC takes fluorescent images automatically. The obtained images are processed by image analysis software integrated inside the system
ADVANTAGE #3
Disposable Microchips
The ADAM™ series automated cell counter utilizes a precision disposable microchip to eliminate the problem of a permanent counting chamber.
Each microchip is designed for single use. Pumping, cleansing, and wasting slides are not necessary for the ADAM™ cell counter.
Each microchip is produced at our state-of-the-art manufacturing facility and validated for accuracy.
ADVANTAGE #3
Accuracy & Reproducibility
ADVANTAGE #4
Comparison with Flow Cytometry
Comparison of cell viability between ADAM™ and flow cytometry.
SK-OV, HeLa and NCI-H23 cells were treated with 100 and 300 μM of H2O2 for 3 hours, then analyzed by ADAM™ and flow cytometry.
Values are given as mean ± SD of three experiments.
Reference paper of using ADAM™-MC
1. 4-1BB signaling activates glucose and fatty acid metabolism to enhance CD8+ T cell proliferation, Cellular & molecular immunology 14.9 (2017): 748-757.
2. The repopulating cancer cells in melanoma are characterized by increased mitochondrial membrane potential, Cancer letters 382.2 (2016): 188-194
3. Phase I Clinical Trial of 4-1BB-based Adoptive T-cell therapy for Epstein-Barr Virus (EBV)-positive tumors, Journal of Immunotherapy (Hagerstown, Md.: 1997) 39.3 (2016): 140.

NanoEntek blog is now open!
Want to learn more about cell counting
and cell therapy?
Visit to find out more!
blog-nanoentek.com

FOR RESEARCH USE ONLY.
This product is not approved for diagnostic or therapeutic use.